

<b>Date and Time:</b>	<b>30<sup>th</sup> January 2013; 10.30 – 16.30hrs</b>
-----------------------	---

<b>Minutes:</b>		
<b>Guideline Development Group Meeting</b>		
<b>Place:</b>	<i>NCGC Boardroom, Great Portland Street, London</i>	
<b>Present:</b>	<p>Philip Conaghan (Chair)  Mark Porcheret (MP)  Ian Bernstein (IB)  Fraser Birrell (FB)  Michael Doherty (MD)  Rob Middleton (RM)  Krycia Dziedzic (KD)  Weiya Zhang (WZ)  Tony Whiting (TW)  Erika Baker (EB)  Elspeth Wise (EW)  Richard Frearson (RF)  Brian Lucas (BL)</p> <p>Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN)  Emmert Roberts, Research Fellow (ER)  Margaret Constanti, Health Economist (MC)  Sue Latchem, Guideline Lead and Operations Director (SL)</p>	
<b>Co-opted experts</b>		
Professor Andrew Price (COAST team)		
<b>Apologies</b>		
Jo Cumming Peter Kay		
<b>NICE</b>		
Ben Doak		
<b>Declarations of Interest</b>		
<b>PC</b> Declared personal non-pecuniary specific interests: PC has revised Map of Medicine OA pathway Speaker at Keele University “Imaging as a biomarker in OA”		
<b>BL</b>		

Declared a personal non-pecuniary specific interest:

Attended the ARMA (Arthritis and Musculoskeletal Alliance) lecture on 21st November 2012 sponsored by Roche.

**EW**

EW took part in a NAPP advisory board meeting on the 28th January regarding genetic variations in metabolising opioids.

**FB**

Declared a personal pecuniary specific interest:

FB is currently writing Osteoarthritis chapter for Landmarks in Rheumatology for Oxford University Press- draft submission September for publication 2014.

**MP**

Declared a personal pecuniary specific interest:

MP is the author of the OA e-learning module on the RCGP musculoskeletal modules, to be launched in Feb 2013 and is sponsored by ARUK.

**KD**

Declared personal non-pecuniary specific interests:

KD is writing a review paper on advances in diagnosis and management of hand OA for a peer-reviewed Rheumatology journal

KD has been appointed as a NICE Fellow for OA dissemination (nonpharma & primary care focus)

There were no changes in any of the other GDG members' or NCGC staff's DOIs since the last meeting.

**MD** left the room at 13.35 for the discussions regarding the paracetamol versus celecoxib comparison (regarding a conflict of interest declared on the 18<sup>th</sup> December GDG meeting)

No further actions were taken following these declarations.

1. Philip Conaghan welcomed the group to the seventh meeting of this GDG. PC asked the GDG for any new DOIs since GDG meeting 1.
2. Emmert Roberts and Margaret Constanti presented the clinical and cost effectiveness evidence related to hyaluronan Injections, nutraceuticals, acupuncture and paracetamol which had been covered in previous meetings.
3. Emmert Roberts and Margaret Constanti presented a new analysis of the safety profile of paracetamol compared to NSAIDs in the management of people with OA.
4. Vanessa Delgado Nunes and PC facilitated the discussion with the GDG on decision-making, revising recommendations and linking evidence to recommendations (LETR) for the OA guideline.
5. Margaret Constanti delivered an update to the GDG on progress in the modelling work

6. Professor Andrew Price delivered a presentation on the Coast Programme systematic review protocol and initial findings.
7. The evidence review protocol on the time to referral to surgery for people with OA was not discussed at this meeting as it was decided that further revisions would need to be undertaken and that discussions with the GDG would take place between meetings. .
8. Philip Conaghan asked the GDG whether there were any items under AOB and closed the meeting at 16.45hrs.

**Date, time and venue of the next meeting**

12<sup>th</sup> March 2013, 10:30 – 16:30hrs.